Latest Breaking News On - Investigational therapies - Page 4 : comparemela.com

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoCourtney okonekAnabel chanAnna skwarskaMichael vasconcellesVenetoclax synergizesPivekimab sunirineRobert stanislaroExchange commissionImmunogen incEuropean medicines agencyDepartment of leukemiaExchange commission onCompany quarterly reports on formAmerican society of hematology

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesKristin yaremaBhagirathbhai dholariaBrian truongStacey cranertPrnewswire poseida therapeutics incAmerican society of hematologyPoseida therapeutics incVanderbilt ingram cancer centerExchange commissionTherapeutics presents positive early resultsRelapsed refractory multiple myelomaAmerican societySan diegoCell therapyAssociate professor

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesPatrick amstutzSeth lewisLaura jeanbartAmerican society of hematologySan diego convention centerHead of portfolio management communicationsAmerican societyAnnual meetingMolecular partnerMyeloid leukemiasInvestigational therapiesExcluding transplantationPreliminary resultsHallsg hPortfolio management

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
joplinglobe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from joplinglobe.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoFrancesco galimiContactsanne bowdidgeMonica morenoStern investor relations incDrug administrationAdicet bio incChief medicalPharmacodynamic profileFirst in class allogeneicDeltat cell therapyRefractory aggressiveb cell non hodgkinEarly phaseInvestigational therapiesFast track designation

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

GlycoMimetics, Inc. , a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American.

United statesEdwin rockNew zealand generalNew zealandBaylor college of medicineMicheles redellEmmanuel almanza huanteGlycomimetics incSan diego convention centerChinese national medical products administrationDrug administrationUniversity of texas md anderson cancer centerCompany annual report on formExchange commissionLeukemia lymphoma societyTexas children cancer center